It has been recently shown that selective HDAC6 inhibition suppresses tumor growth and restores sensitivity to chemotherapeutics (Oliveira-Silva et al., 2025a; Won et al., 2018) or antitumor agents (Huang et al., 2024; Peng et al., 2017). Here, HDAC6 is linked to neoplasm.